para- aminomethylbenzoic acid
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Surname | Para-aminomethylbenzoic acid | |||||||||||||||
other names |
|
|||||||||||||||
Molecular formula | C 8 H 9 NO 2 | |||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
ATC code | ||||||||||||||||
Drug class |
Fibrinolysis inhibitor |
|||||||||||||||
properties | ||||||||||||||||
Molar mass | 151.16 g mol −1 | |||||||||||||||
Melting point |
> 300 ° C |
|||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
The para -Aminomethylbenzoesäure (trade name: Pamba (D), manufacturer: Takeda ) is the amino acid lysine structurally related substance ( analog ) and one of the ε-amino carboxylic acids . As a medicinal substance , it is used medicinally to promote hemostasis.
Para- aminomethylbenzoic acid belongs to the group of antifibrinolytics , which means that the substance inhibits the dissolution of clots ( fibrinolysis ).
effect
Para- aminomethylbenzoic acid inhibits the formation of active plasmin from plasminogen by attachment to the plasmin binding site for lysine . This suppresses the accumulation of plasmin on fibrin or fibrinogen and consequently the clot dissolution (fibrinolysis) is inhibited.
The mode of action is similar to that of the structurally similar ε-aminocarboxylic acid tranexamic acid .
The elimination half-life in the blood plasma is about one to two hours with an effect of four to six hours. Para- aminomethylbenzoic acid is largely excreted unchanged via the kidneys.
para- Aminomethylbenzoic acid is well absorbed and can be administered both parenterally and orally .
application
In medicine, para- aminomethylbenzoic acid is u. a. Used as an antidote for the treatment of hyperfibrinolysis , triggered by fibrinolytics , or in rare, congenital disorders in the production of fibrinolysis inhibitors.
Treatment with para- aminomethylbenzoic acid should be carried out under the supervision of a doctor experienced in the treatment of coagulation disorders and only if other therapeutic measures are not sufficient.
Individual evidence
- ↑ a b c data sheet 4- (aminomethyl) benzoic acid from Sigma-Aldrich , accessed on November 7, 2016 ( PDF ).
- ↑ K. Aktories, U. Förstermann, W. Forth: General and special pharmacology and toxicology. 9th edition, Elsevier, Urban & FischerVerlag, 2006, p. 547, ISBN 978-3-437-44490-6 .
- ↑ a b C.-J. Estler, H. Schmidt (Ed.): Pharmacology and Toxicology. 6th edition, Schattauer Verlag, 2007, pp. 547-547, ISBN 978-3-7945-2295-8 .
- ↑ technical information Gumbix, May 2005, professional information PAMBA May of 2005.